Long-acting inhaled beta 2-agonists in the management of asthma: recent advances and current recommendations.
Salmeterol and formoterol belong to a new class of inhaled beta 2-agonists with a prolonged duration of action. At the time these agents were introduced, there was uncertainty regarding the safety of beta 2-agonist therapy in asthma and concern that they might lead to a deterioration in asthma control. Recent studies, in contrast, have demonstrated both their safety and therapeutic efficacy. The aims of this review are to highlight these new developments and to consider the place of these long-acting beta 2-agonists in asthma management strategies.
Redington
A E
AE
Department of Respiratory Medicine, United Medical School of Guy's Hospital, London.
Rees
P J
PJ
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000420:Albuterol / Q000031:analogs & derivatives / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D004983:Ethanolamines / Q000627:therapeutic use; D005541:Forced Expiratory Volume / Q000502:physiology; D000068759:Formoterol Fumarate; D017408:Guidelines as Topic; D006801:Humans; D010366:Peak Expiratory Flow Rate / Q000502:physiology; D000068299:Salmeterol Xinafoate; D016896:Treatment Outcome
D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D004983:Ethanolamines; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D000068759:Formoterol Fumarate